Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of Enbrel for prior etanercept trial participants with rheumatoid arthritis or juvenile idiopathic arthritis
2012-001145-40Phase 3
- Sponsor
- Amgen
- Start
- Mar 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etanercept in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), sponsored by Amgen.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2012-001145-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001145-40.